[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Children's Hospital Basel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":253},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,76,107,137,164,198,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100589417","restricted-versus-liberal-fluid-intake-for-prevention-of-bronchopulmonary-dysplasia-100589417",false,"NCT06954142","Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia","Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia - RELIEF Trial. A Cluster-randomised Multiple Period Cross-over Trial.","RELIEF","Inclusion Criteria:\n\n* Hospitalised preterm infants born before 30 weeks 0 days gestation\n* Signed informed consent for further research use of health-related data\n\nExclusion Criteria:\n\n* congenital malformations\n* diseases likely to affect life expectancy, lung function, fluid strategy, or neurodevelopment\n* renal disease requiring fluid management outside the clinical standard of care\n* congenital heart disease not including patent ductus arteriosus (PDA)","ALL","8 Days",{"count":20,"type":21},750,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to determine whether restricted fluid intake (135 ±5 mL\u002Fkg\u002Fday) compared to liberal fluid intake (165 ±5 mL\u002Fkg\u002Fday) from day 8 of life reduces the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age or prior death in preterm infants born \\\u003C30 weeks gestational age.",[27],"Bronchopulmonary Dysplasia",[29,30],"Fluid Restriction","Preterm Infants","RECRUITING","2026-05-04",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2025-07-12",{"date":39,"type":21},"2029-12",{"name":41,"class":42},"University Children's Hospital Basel","OTHER",9,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100582301","a-swiss-assessment-of-hypothalamic-pituitary-adrenal-axis-suppression-after-glucocorticoid-therapy-for-leukemia-and-lymphoblastic-lymphoma-in-children-100582301","NCT06861530","A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children","A Swiss Prospective Multicenter Longitudinal Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children: An Explorative Study","LeukemiaCort","Inclusion Criteria:\n\n* diagnosed with ALL or LBL\n* treated for at least 21 sequential days with glucocorticoids between the 01.07.2024 and the 30.06.2027 at the Childrens University Hospital of Basel or at the Childrens Hospital of Aarau\n* lnformed consent can be obtained from the patient\\'s legal representatives (and the patient if at least 14 years of age) within week 2 of treatment with glucocorticoids\n\nExclusion Criteria:\n\n\\- Contraindication to the administration of intravenous synthetical ACTH (Synacthen®): extremely rare cases of known or suspected hypersensitivity to Synacthen®.","18 Years",{"count":54,"type":21},40,"OBSERVATIONAL","Plain Language Summary:\n\nBackground Glucocorticoids are stress hormones produced by the human body to control inflammation and regulate the immune system. Cortisol is the most well-known example of a glucocorticoid. These stress hormones are essential for the bodys healthy functioning.\n\nTo treat certain types of cancer, such as leukemia (blood cancer) in children, glucocorticoids are administered as medications in large quantities. This helps rapidly reduce the number of cancer cells in the body but also leads to the suppression of the body's natural glucocorticoid production, causing a deficiency.\n\nThis deficiency can be particularly dangerous for children with leukemia, as their immune defenses are already weakened by chemotherapy, leading to an increased risk of infections. Moreover, the signs of glucocorticoid deficiency in children with leukemia are often indistinguishable from the side effects of chemotherapy, making the deficiency harder to detect.\n\nObjectives The aim of the study is to understand how frequently and for how long the body's natural glucocorticoid production is impaired in children treated for lymphoblastic leukemia and lymphoblastic lymphoma. Additionally, the goal is to identify which children are at particularly high risk.\n\nBy gaining a better understanding, this study may help to improve the detection and treatment of glucocorticoid deficiency in children with blood cancer.\n\nMethods Regular low-dose ACTH tests will be conducted to assess the bodys natural glucocorticoid production during and after treatment. To avoid placing additional burden on children who are already heavily affected by the disease, these tests will only be performed when there is already a venous access established and the children are in the hospital for treatment reasons.",[58,59,60],"Adrenal Insufficiency","Leukemia, Lymphoblastic, Acute, Pediatric","Lymphoma, Lymphoblastic",[62,63,64,65,66,67,68],"Adrenal insufficiency","leukemia","leukaemia","childhood","pediatric","paediatric","glucocorticoid",{"date":34,"type":35},{"date":71,"type":35},"2024-08-13",{"date":73,"type":21},"2026-12-31",{"name":41,"class":42},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100486298","electrical-impedance-tomography-for-identification-of-optimal-positive-end-expiratory-pressure-in-newborn-infants-100486298","NCT05612256","Electrical Impedance Tomography for Identification of Optimal Positive End-expiratory Pressure in Newborn Infants","Inclusion Criteria:\n\n* 22+0 to 41+6 weeks' gestational age\n* Requiring mechanical ventilation\n* Written informed parental consent\n\nExclusion Criteria:\n\n* Major congenital malformations including lung and cardiac malformations\n* Infants on high frequency oscillatory ventilation\n* Lack of written informed parental consent","0 Days","28 Days",{"count":85,"type":21},86,"Electrical impedance tomography (EIT) enables assessment of regional lung ventilation at the bedside. EIT has been safely used in newborn infants to image intrathoracic lung volume patterns as early as from the first minute of life. This prospective single-centre observational study is to identify optimal PEEP in infants on respiratory support by measurements of EIT, FOT and SOPI.",[88],"Positive End-expiratory Pressure (PEEP)",[90,91,92,93,94,95,96,97,98,99],"respiratory support","newborn infants","ventilator induced lung injury (VILI)","mechanical ventilation","electrical impedance tomography (EIT)","forced oscillation technique (FOT)","saturation oxygenation pressure index (SOPI)","ventilation to perfusion ratio","regional lung ventilation patterns","Silent Spaces",{"date":34,"type":35},{"date":102,"type":35},"2022-12-10",{"date":104,"type":21},"2026-12",{"name":41,"class":42},1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100472073","early-pulmonary-dysfunction-in-childhood-cancer-patients-100472073","NCT05427136","Early Pulmonary Dysfunction in Childhood Cancer Patients","Prospective Multicentre Cohort Study of Early Pulmonary Dysfunction in Childhood Cancer Patients (SWISS-Pearl Study)","SWISS-Pearl","Inclusion Criteria:\n\n* at least one of the following cancer treatments:\n\n  * chest radiation\n  * treatment with any kind of chemotherapy\n  * hematopoietic stem cell transplantation (HSCT)\n  * thoracic surgery\n* consent for Childhood Cancer Registry (ChCR) registration\n\nExclusion Criteria:\n\n* no signed informed consent\n* Operation outside the chest area as only cancer treatment\n* Relapsed cancer (patients who develop relapse during the study will not be excluded)\n* In addition for MRI and lung function tests:\n\n  * Subjects who are respiratory insufficient and cannot perform a lung function test (less than 92% O2 saturation; under O2 therapy)\n  * Pregnant\n  * MRI measurement not possible without sedation\n  * Metal (e.g. pacemaker) in the body","4 Years","22 Years",{"count":118,"type":21},140,"This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.",[121],"Pulmonary Dysfunction",[123,124,125,126,127,128,129],"Childhood cancer","Lung function","Lung imaging","Breath analysis","Exome-wide association studies (EWAS)","Genome-wide association studies (GWAS)","Pulmotoxic treatment",{"date":34,"type":35},{"date":132,"type":35},"2021-06-01",{"date":134,"type":21},"2051-06",{"name":41,"class":42},5,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":116,"enrollmentInfo":145,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":106},"100397953","exhaled-breath-analysis-by-secondary-electrospray-ionization---mass-spectrometry-in-children-and-adolescents-100397953","NCT04461821","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents","Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents (EBECA)","EBECA","Inclusion Criteria:\n\n* Age 0 ≤ 22 years at study entry and signed informed consent\n\nAdditional inclusion criteria for respiratory disease population:\n\n* Acute disease: - Acute signs for a respiratory disease, indicated by e.g. increased work of breathing (e.g. dyspnea, increased respiratory rate), cough or wheezing.\n* Chronic disease: - Suspected or confirmed chronic airway disease (e.g. asthma).\n\nAdditional inclusion criteria for neurological disease population:\n\n* Acute disease: - Acute presentation or report within 24 hours of any signs of neurological deficit (motor function, sensoneural, or verbal).\n* Chronic disease: - Confirmed chronic neurologic disease (e.g. childhood epilepsy).\n\nAdditional inclusion criteria for T1D disease population:\n\n* Acute disease: - Hyperglycemia and\u002For pH (venous) \\\u003C7.3, bicarbonate \\>10 mmol\u002FL, increased levels of acetone in blood or urine in the context of newly diagnosed or known T1D.\n* Chronic disease: - Confirmed diagnosis of T1D\n\nExclusion Criteria:\n\n* Physical or intellectual impairment precluding protocol adherence.\n\nAdditional exclusion criteria for respiratory disease population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and\u002For pharmacological treatment and is associated with an inflammatory response, relevant congenital defects\n\nAdditional exclusion criteria for neurological disease population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and\u002For pharmacological treatment and is associated with an inflammatory response, relevant congenital defects.\n\nAdditional exclusion criteria for T1D population:\n\n* Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), relevant congenital defects.",{"count":146,"type":21},3600,"This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.",[149,150,151],"Respiratory Diseases","Neurological Disorders","Type 1 Diabetes",[153,154,155,156,157],"Exhaled breath analysis","Therapeutic drug monitoring (TDM)","Secondary Electrospray ionization - mass spectrometry (SESI-MS)","breath analysis platform","breath metabolomics",{"date":34,"type":35},{"date":160,"type":35},"2020-09-11",{"date":162,"type":21},"2030-07",{"name":41,"class":42},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":136},"100629254","design-development-and-evaluation-of-a-digital-health-assistant-for-paediatric-asthma-100629254","NCT07472283","Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma","ALEX","Observational study population:\n\nInclusion Criteria:\n\n* Written informed assent or consent, and parental\u002Fcaregivers consent, depending on age.\n* Age 10 to 19 years.\n* Sufficient understanding of the Romanian language.\n* Digital literacy, including the parents\u002Fcaregivers, as assessed by the treating physician and\u002For by the recruiting healthcare provider using a multiple-choice questionnaire administered to the patient and their parents after a brief introduction to the functionalities of the Alex app.\n* Confirmed asthma, i.e., history of recurrent wheeze, at least one spirometry in the three years prior to inclusion showing reversible obstruction (increase in forced expiratory volume at one second (FEV1) of ≥12% and\u002For ≥200ml) and\u002For a positive airway challenge test142.\n* Participants need to be under treatment with regular prescribed asthma drugs, including inhaled corticosteroids, Long-acting β adrenoceptor agonists (LABA), and\u002For leukotriene receptor antagonists at recruitment, with no change in their medication in the last month.\n\nExclusion Criteria:\n\n* Inability to perform adequate lung function measurements due to physical and\u002For intellectual disability.\n* Acute asthma exacerbation requiring systemic corticosteroids within four weeks prior to recruitment.\n* Not willing to use smartphones.\n* Underlying chronic respiratory disease other than asthma (cystic fibrosis, primary ciliary dyskinesia).\n* Acute lower respiratory tract infections (e.g., pneumonia, bronchitis) diagnosed by physician within past 4 to 6 weeks. For tuberculosis, see next exclusion criterion.\n* Active tuberculosis as per Quantiferon test.\n* Other causes of nocturnal cough such as postnasal drip, and vocal cord dysfunction.\n* Active smoking as per urinary Cotinin test.\n* Substance abuse as per urinary drug test.\n\nQualitative study population:\n\nInclusion criteria:\n\n* Enrolled in the observational study\n* Have had access to the DHA for at least 6 weeks\n* Provide informed assent (and parental\u002Fguardian consent where applicable) or consent, according to age\n* Able to participate in interviews or group discussions in Romanian\n\nExclusion criteria:\n\n* Significant cognitive or communication difficulties that would limit participation in interviews or group discussions\n* Withdrawn from the observational study prior to data collection for qualitative work","10 Years","19 Years",{"count":174,"type":21},42,"This study is to evaluate the efficacy of the digital health assistant (DHA) \"Alex\" in improving asthma control in asthmatic children and adolescents aged 10 to 19 compared to their baseline values. It is designed to track over a period of six consecutive months lung function parameters, lung inflammation, asthma symptoms and burden, medication adherence, and passively recorded nocturnal asthma symptoms and markers related to sleep quality.\n\nIn Phase I (months 1-3), Digital Health Assistant (DHA) 's core functionality will be deployed.\n\nIn Phase II (months 3-6), the platform will be augmented with lung-function-fluctuations analysis-informed therapeutic recommendations, allowing to quantify the incremental benefit of targeted decision support beyond the gamified DHA alone.\n\nAn embedded qualitative study will be conducted to evaluate acceptability of and engagement with the DHA.",[177],"Paediatric Asthma",[179,180,181,182,183,184,185,186,187,188],"Artificial Intelligence (AI)","Chronic Obstructive Pulmonary Disease (COPD)","Digital Health Assistant (DHA)","Fractional Exhaled Nitric Oxide (FeNo)","Arterial blood oxygen saturation (SpO2)","In-depth Interview (IDI)","Focus Group Discussion (FGD)","Gamification","Digital health technologies","Asthma control","NOT_YET_RECRUITING","2026-03-13",{"date":192,"type":35},"2026-03-16",{"date":194,"type":21},"2026-04",{"date":196,"type":21},"2027-05",{"name":41,"class":42},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":52,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":75},"100582518","prospective-evaluation-of-optithydose-100582518","NCT06864351","Prospective Evaluation of OptiThyDose","Prospective Evaluation of OptiThyDose, a Mathematical Model for Calculating Appropriate Dose Ranges in Children With Thyroid Diseases","Inclusion Criteria:\n\nCongenital hypothyroidism (CH)\n\n* Newborns with pathological neonatal screening and confirmation of an increased Thyrotropin (TSH) level in an independent venous blood sample\n\nGraves' disease (GD)\n\n* Children until 18 years with new diagnosis of GD, recurrence of GD, or insufficiently controlled GD under CMZ\u002FMMZ during follow-up according to:\n\n  * Pathological lab values (suppressed TSH, increased thyroid hormone levels, positive Anti-TSH-receptor antibodies)\n  * Typical clinical picture, if present (goitre, tachycardia, palpitations, weight loss, hyperphagia, altered mood)\n\nCH and GD\n\n* The study participant must be accessible for scheduled visits, treatment and follow-up.\n* Signed Informed Consent form (ICF) obtained prior to any study related procedure. Written IC for study participation must be signed and dated by the patient and\u002For his\u002Fher legal representative(s) in accordance with national legal requirements\n\nExclusion Criteria:\n\nCH and GD\n\n* Exclusion of newborns from mothers with GD\n* Exclusion of patients in case of a life-threatening event\n\nGD\n\n* Exclusion of children with known other aetiologies of hyperthyroidism than GD without elevated Anti-TSH-receptor antibodies e.g.:\n\n  * known toxic thyroid nodules proven by ultrasound\u002Fscintigraphy\n  * known amiodarone induced hyperthyroidism\n  * known McCune Albright syndrome (based on clinical, laboratory, and genetic diagnosis) associated hyperthyroidism\n  * known genetically proven hyperthyroidism caused by activating mutations of the TSH receptor gene",{"count":206,"type":21},150,[24],"The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).",[210,211,212],"Thyroid Diseases","Congenital Hypothyroidism","Graves Disease","2025-09-01",{"date":215,"type":35},"2025-09-03",{"date":217,"type":35},"2025-08-28",{"date":219,"type":21},"2029-02",{"name":41,"class":42},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":229,"enrollmentInfo":230,"targetDuration":232,"studyType":55,"phases":4,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":5},"100289188","diagnosis-of-tuberculosis-in-swiss-children-100289188","NCT03044509","Diagnosis of Tuberculosis in Swiss Children","Evaluation and Validation of Novel Immunodiagnostic Tests for Childhood Tuberculosis Infection and Disease in Switzerland. The CITRUS (ChIldhood TubeRcUlosis in Switzerland) Study.","CITRUS","Inclusion Criteria:\n\n* all children \u002F adolescents \\\u003C 18 years of age undergoing evaluation for TB exposure, infection or disease.\n\nExclusion Criteria:\n\n* children \u002F adolescents with TB infection or disease who have already been started on anti-mycobacterial treatment, children who have been treated for TB previously.","17 Years",{"count":231,"type":21},190,"2 Months","1. The primary objective is to improve the sensitivity of novel immunodiagnostic tests for detection of TB disease in children.\n2. The secondary objective is to determine biomarkers that discriminate children with TB infection and disease.",[235,236],"Tuberculosis","Mycobacterium Tuberculosis",[238,239,240,241,242,243,244],"Immunodiagnostics tests","TB exposure","Latent TB","TB disease","Biomarkers","Metabolomics","NMR","2024-09-05",{"date":247,"type":35},"2024-09-19",{"date":249,"type":35},"2017-05-12",{"date":251,"type":21},"2028-12",{"name":41,"class":42},""]